Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 8/20 | 0.55 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.55 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4628496 | 0.86 | MAPT (0.79) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4626978 | 0.85 | MAPT (0.65) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4626761 | 0.85 | MAPT (0.58) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL4626845 | 0.83 | MAPT (0.62) | MAPTTDP1TSHRPTGDR2PTGDR | |
| SCHEMBL158457 | 0.81 | MAPT (0.67) | MAPTTDP1TSHRESR1POLB | |
| SCHEMBL29860787 | 0.81 | MAPT (0.67) | MAPTTDP1TSHRESR1POLB | |
| SCHEMBL4626233 | 0.80 | MAPT (0.68) | MAPTTDP1TSHRPTGDR2PTGDR | |
| Ammonia Solution, Strong SCHEMBL29010268 | 0.80 | MAPT (0.65) | MAPTTDP1TSHRESR1POLB | |
| SCHEMBL4887815 | 0.80 | ESR1 (0.72) | MAPTTDP1TSHRESR1POLB | |
| SCHEMBL4627361 | 0.79 | PTGDR (0.58) | MAPTTDP1TSHRPTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | claimed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | claimed |
| US-20080312322-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-12-18 | — | — | US | disclosed |
| EP-1888505-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125593-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312322-A1 | Organic Compounds | NR3C2, MRGPRX2, HRH2 | MAPT 4232/4885TDP1 4717/4885TSHR 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.